Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2009
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which develops and markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $251,142 | $242,772 |
| Gross Profit | $142,135 | $142,882 |
| Gross Margin | 57% | 59% |
| Operating Income | $32,780 | $19,951 |
| Net Income | $23,873 | $6,877 |
| Diluted EPS | $0.53 | $0.15 |
| Operating Cash Flow | $24,904 | $(5,592) |
| Total Debt (Short + Long Term) | $913,156 | $904,794 |
| Cash and Equivalents | $1,885 | $3,226 (Beginning of period) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3% ($8.4 million) year-over-year, driven by a 4% increase in CooperVision sales and a 1% increase in CooperSurgical sales. Growth was supported by volume increases in single-use and silicone hydrogel lenses.
- Profitability Surge: Operating income rose 64% to $32.8 million, and Net Income increased 247% to $23.9 million. This improvement was primarily due to a 14% reduction in Selling, General, and Administrative (SG&A) expenses and a significant increase in "Other income, net."
- Expense Management: SG&A expenses decreased from $109.9 million to $95.0 million, largely due to reduced share-based compensation and lower litigation costs. Restructuring costs increased to $2.95 million from $0.82 million due to a new global restructuring plan at CooperVision.
- Non-Operating Items: "Other income, net" jumped from $0.6 million to $8.1 million, driven by a $6.5 million foreign exchange gain and a $1.8 million gain on the extinguishment of debt.
- Cash Flow: Operating cash flow turned positive at $24.9 million compared to a $5.6 million outflow in the prior year, attributed to higher net income and improved receivables collection.
Guidance, Outlook, and Risks
- Outlook: Management expects the contact lens market to perform better than the broader economy despite recessionary pressures. They anticipate continued growth in silicone hydrogel products and market penetration in Europe and Asia.
- Liquidity: The Company maintains $1.9 million in cash and cash equivalents and $117.8 million in available borrowing capacity under its $650 million revolving credit facility. Management believes these resources are sufficient to fund operations, capital expenditures, and dividends for the next 12 months.
- Restructuring: CooperVision initiated a "Critical Activity" restructuring plan with estimated total costs of $4.0 million, expected to be completed by the third quarter of fiscal 2009.
- Risks: Key risks include the global economic downturn affecting credit markets and consumer spending, competition in the silicone hydrogel toric lens market, and potential goodwill impairment due to stock price declines. The Company is also subject to ongoing securities litigation.
Investor Verification Checklist
- Debt Repurchase Gain: Verify the $1.8 million gain on debt extinguishment and its impact on the effective tax rate (19% vs 27.5% prior year).
- Foreign Exchange Impact: Assess the sustainability of the $6.5 million foreign exchange gain, which was driven by the strengthening U.S. dollar.
- Restructuring Costs: Monitor the execution of the $4.0 million restructuring plan and its impact on future operating expenses.
- Legal Proceedings: Review the status of the securities class action litigation (trial date set for February 2010) and the settled Bausch & Lomb patent dispute.
- Product Mix Shift: Evaluate the margin impact of the shift toward lower-margin single-use spherical lenses versus higher-margin silicone hydrogel products.